Insights about U.S. Stocks that landed in the Green-Zone during Thursday’s trade, are depicted underneath:

Insmed Incorporated (NASDAQ:INSM)’s shares picked up 7.00%, and closed at $20.33, hitting new 52-week high of $20.60.

Formerly on February 27, Insmed Incorporated (INSM), stated financial results for the fourth quarter and year ended December 31, 2014.

Highlights of the fourth quarter of 2014 and recent weeks comprise:

• Received validation of the Corporation’s Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ARIKAYCE following the approval of the Pediatric Investigation Plan (PIP) by the EMA’s Pediatric Committee;
• Advanced progress of the Corporation’s phase 3 global trial (the “212” trial) for patients with treatment resistant nontuberculous mycobacteria (NTM) lung infections counting the activation of multiple clinical trial sites;
• Designated Myrtle Potter to its Board of Directors;
• Designated Dr. Olaf Bartsch as Vice President - Europe, General Manager - Germany and Dr. Francois Cornu as Vice President - Europe, General Manager - France to commence the build-out of operations in Europe. Both Drs. Bartsch and Cornu will report to Will Lewis, President and Chief Executive Officer;
• Launched a comprehensive NTM disease state awareness website www.ntmfakten.de for the education of healthcare providers in Germany.
• Reached a partnership with the European Respiratory Society (ERS) that established an inaugural award in NTM research entitled, ERS Research Award: Innovation in Non-Tuberculous Mycobacteria Science and Medicine, which is designed to advance the science and understanding of NTM lung disease; and
• Corporation to host an Analyst and Investor Day in New York City on Tuesday, March 24.

Insmed Incorporated is a biopharmaceutical corporation dedicated to improving the lives of patients battling serious lung diseases. Insmed is focused on the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections. Insmed is also focused on the development of INS1009, the Corporation’s inhaled treprostinil pro-drug for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs.

Anthera Pharmaceuticals Inc (NASDAQ:ANTH), raised 6.96%, and closed at $5.53, hitting new 52-week high of $5.61. The stock has the beta value of 1.77, and its volatility for the week is 7.55%, while for the month it is 11.07%. The company has the market capitalization of $144.11M. The mean recommendation of analysts for this stock is 2.70.(where 1=Buy, 5=Sale).

Anthera Pharmaceuticals, Inc., a biopharmaceutical corporation, focuses on developing and commercializing products to treat diseases associated with inflammation and autoimmune diseases.

W&T Offshore, Inc (NYSE:WTI), enhanced 6.86%, and closed at $6.23.

W&T Offshore Inc. (WTI), stated its year-end 2014 proved reserves, fourth quarter and full year 2014 operations and financial results, 2015 capital budget and drilling plans, and 2015 production and expense guidance.

Production, Proceeds and Price:

For the fourth quarter of 2014, our oil production was 1.8 million barrels, up 2.1% over the fourth quarter of 2013. NGL production was 567,000 barrels, down slightly from the fourth quarter of 2013. Natural gas production was 13.1 billion cubic feet (“Bcf”) for the fourth quarter of 2014 contrast to 16.8 Bcf in the fourth quarter of 2013. Natural gas production volumes for the fourth quarter of 2013 were affected by a cumulative volume adjustment associated with previous periods, which resulted in a one-time positive adjustment of 2.6 Bcf in the fourth quarter of 2013. In January of 2014, the Corporation identified an erroneous MMBtu conversion factor it had been receiving from a third party that had the effect of understating natural gas production at our Viosca Knoll 783 field (“Tahoe”) since we attained the field in 2011. This adjustment did not affect proceeds or cash flows but did influence formerly stated natural gas production volumes and the resultant calculation of depletion expense.

For the full year of 2014, our oil production was 7.2 million barrels, up 2.3% over calendar year 2013. NGL production was 2.1 million barrels, up 1.0% over 2013, and natural gas production was 50.1 Bcf, down 6.0% from 2013. The continued focus on increasing oil production over natural gas production was evident in 2014 with our successful exploration and development program focused on oil production and through attainments.

Proceeds for the fourth quarter of 2014 were $196.7 million contrast to $244.9 million in the fourth quarter of 2013. Proceeds reduced on a steep decline in crude oil prices, which were down $23.39 per barrel between the two quarters. NGLs prices declined $12.81 per barrel as a result of the decline in crude oil prices. Natural gas prices were higher by $0.66 per Mcf. During the fourth quarter of 2014, our average realized sales price was $70.72 per barrel for oil, $26.97 per barrel for NGLs and $3.81 per Mcf for natural gas. On a combined basis, we sold about 50,000 Boe per day at an average realized sales price of $42.46 per Boe contrast to 56,100 Boe per day sold at an average realized sales price of $47.33 per Boe in the fourth quarter of 2013.

Proceeds for the full year of 2014 were $948.7 million contrast to $984.1 million in calendar year 2013. Proceeds were lower despite the rise in oil and NGL production on an 11.2% decline in crude oil prices to $90.96 per barrel. For the year 2014, we sold on average 48,300 Boe per day at an average realized sales price of $53.49 per Boe contrast to 49,300 Boe per day sold at an average realized sales price of $54.58 per Boe in calendar year 2013.

W&T Offshore, Inc. is an independent oil and natural gas producer with operations offshore in the Gulf of Mexico and onshore in the Permian Basin of West Texas. We have grown through attainments, exploration and development and presently hold working interests in about 63 offshore fields in federal and state waters (61 producing and two fields capable of producing).

Peregrine Pharmaceuticals (NASDAQ:PPHM), enhanced 6.80%, and closed at $1.57.

Peregrine Pharmaceuticals, Inc. (PPHM), a biopharmaceutical corporation focused on advancing bavituximab, a novel immuno-oncology agent in Phase III development, declared that it will report financial results for the third quarter fiscal year (FY) 2015 ended January 31, 2015 on March 12, 2015 after market and will host a conference call and webcast at 1:30 PM Pacific Daylight Time (4:30 PM Eastern Daylight Time). Peregrine’s senior administration will talk about financial results for the third quarter ended January 31, 2015 of FY 2015 and will review recent progress of its clinical development programs.

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical corporation with a pipeline of novel drug candidates in clinical trials for the treatment and diagnosis of cancer. The corporation’s lead immuno-oncology candidate, bavituximab, is in Phase III development for the treatment of second-line non-small lung cancer together with several investigator-sponsored trials evaluating other treatment combinations and additional oncology indications.